Eli Lilly takes aim at illicit market for its experimental weight-loss drug

Eli Lilly has initiated legal action against six companies selling versions of its experimental weight-loss drug, retatrutide. The lawsuit is part of a broader effort to combat a burgeoning illicit market for the drug, which is currently in clinical trials and not approved by the FDA. Despite the ban on unapproved drugs under federal law, numerous telehealth firms, clinics, and online vendors have been selling retatrutide, fueled by promising trial results and social media hype.

Max Denning, an associate vice president at Eli Lilly, emphasized that the six lawsuits are merely the beginning and called for regulators, social media companies, and payment processors to join efforts in curbing the illicit sales. The lawsuits target companies such as Astra Peptides, Legendary Peptides, Texas Peptides, Lone Star Peptide, Aesthetic Envy, and Striker Pharmacy.

The latter two have since removed their retatrutide-related webpages. Eli Lilly's drug is being manufactured overseas and is being marketed as a 'research use only' product, which many consumers are interpreting as a permit for self-administration. The company claims that the illicit sales not only endanger consumers but also tarnish its reputation, as those who experience adverse effects from the unvetted products will associate them with retatrutide and Eli Lilly.